Tarlatamab (Imdelltra; AMG 757; CAS 2491116-37-9): NIOSH HD Category 1 SIXTY-NINTH Mechanism Class [FIRST DLL3 (Delta-like Ligand 3; Notch Pathway Inhibitory Ligand; SCLC Neuroendocrine Aberrant Surface Display via ASCL1/NEUROD1 Transdifferentiation) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761336; May 16, 2024; Accelerated Approval R/R ES-SCLC ≥2 Prior Lines; Amgen)] + FIRST HALF-LIFE EXTENDED (HLE) BiTE EVER FDA APPROVED IN ANY INDICATION (IgG1 Fc → FcRn Recycling → t½ ∼10 Days Q2W IV vs Blinatumomab [Class 57] t½ ∼1–2 h 28-Day CADD Pump) + FIRST SUCCESSFUL DLL3-TARGETING THERAPY EVER (After Rova-T DLL3-ADC TAHOE OS HR 1.46 Failure); Amgen Thousand Oaks CA Cority ÷10; Amgen Manufacturing Breda Netherlands VelocityEHS ÷10; MD Anderson Houston TX EHS Insight ÷10; Glyphward Threshold 22; 642nd Adversarial Attack; 147th Long-Form Blog

Tarlatamab (Imdelltra®; AMG 757; CAS 2491116-37-9; MW ∼75,000 Da bispecific fusion protein [anti-DLL3 scFv + anti-CD3ε scFv + single IgG1 Fc chain]; NIOSH HD Category 1; BLA 761336; MECHANISM: SIXTY-NINTH MECHANISM CLASS in the 642-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST DLL3 (DELTA-LIKE LIGAND 3; DSL FAMILY NOTCH PATHWAY INHIBITORY LIGAND; GENE 19q13.2; MW ∼75 kDa; NORMALLY INTRACELLULAR CIS-INHIBITORY NOTCH LIGAND IN GOLGI → ABERRANT PLASMA MEMBRANE SURFACE TRAFFICKING IN SCLC VIA ASCL1/NEUROD1 NEUROENDOCRINE TRANSDIFFERENTIATION; ~80–85% ES-SCLC DLL3+; ABSENT ON NORMAL BRONCHIAL/ALVEOLAR EPITHELIUM) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE (BLA 761336 MAY 16, 2024; ACCELERATED APPROVAL; R/R EXTENSIVE-STAGE SCLC ≥2 PRIOR PLATINUM-BASED LINES); FIRST HALF-LIFE EXTENDED (HLE) BiTE EVER FDA APPROVED: IgG1 FC APPENDED → FcRn pH6 RECYCLING → t½ ∼10 DAYS (vs blinatumomab [CLASS 57; tandem scFv; no Fc; MW ∼54 kDa; t½ ∼1–2 h; 28-DAY CONTINUOUS IV CADD PUMP]) → Q2W IV DOSING; FIRST SUCCESSFUL DLL3-TARGETING THERAPY EVER: rovalpituzumab tesirine (Rova-T; DLL3-ADC; SG3249 PBD dimer; AbbVie) FAILED TAHOE PHASE 3 OS HR 1.46 vs topotecan; DeLLphi-301 Phase 2: 10 mg Q2W ORR 40.0%; mDOR 9.7 months; mOS 14.3 months; CRS 51.2% Grade 3 1.7%; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 642nd adversarial attack; 147th long-form blog).

SIXTY-NINTH MECHANISM CLASS: DLL3 as a Novel SCLC Target and the Aberrant Neuroendocrine Surface Display Paradox

The sixty-eighth mechanism class — talquetamab (Talvey; first GPRC5D×CD3 bispecific T-cell engager ever; first bispecific against any GPCR; DuoBody IgG4; attack #641; blog #146) — validated the GPCR superfamily as a bispecific T-cell engager target in multiple myeloma. The SIXTY-NINTH CLASS extends the bispecific T-cell engager modality into an entirely different oncology setting — extensive-stage small cell lung cancer (ES-SCLC) — via a neuroendocrine surface marker with a fundamentally distinct presentation in malignant vs normal cells.

DLL3 (DELTA-LIKE LIGAND 3) TARGET BIOLOGY: DLL3 (gene chromosome 19q13.2; MW ∼75 kDa; 618 amino acids; N-terminal DSL [Delta-Serrate-Lag-2] motif; eight EGF-like repeats; single-pass transmembrane domain; DSL protein family) was identified as a cell-surface SCLC therapeutic target through comparative transcriptomic and proteomic profiling of SCLC patient specimens vs matched normal bronchial epithelium. DLL3 is HIGHLY EXPRESSED AT THE PLASMA MEMBRANE SURFACE of SCLC tumor cells while being ABSENT at the surface of normal bronchial epithelial cells, alveolar cells, and normal pulmonary neuroendocrine cells (NECs). This differential surface expression creates a therapeutic window exploitable by a bispecific T-cell engager.

THE DLL3 SURFACE DISPLAY PARADOX: DLL3 is a canonical NOTCH PATHWAY INHIBITORY ligand — one of five Notch receptor ligands (DLL1, DLL3, DLL4, Jagged-1, Jagged-2). Unlike DLL1, DLL4, Jagged-1, and Jagged-2 (trans-activating ligands that activate Notch signaling on NEIGHBORING cells), DLL3 functions exclusively as a CIS-INHIBITORY LIGAND: DLL3 remains on the same cell as the Notch receptor (cis), retaining Notch receptors in the endoplasmic reticulum/Golgi and preventing plasma membrane delivery → inhibits trans-activation by DLL1/DLL4/Jagged ligands from neighboring cells → maintains neuroendocrine progenitor state. In NORMAL cells: DLL3 is an intracellular protein residing in Golgi apparatus and early endosomes, NOT surface-displayed. The molecular retention signals include di-leucine DXXLL endosomal sorting motifs in the cytoplasmic tail and retromer complex VPS35 recognition → endosome-to-Golgi retrieval.

SCLC ABERRANT SURFACE TRAFFICKING VIA ASCL1/NEUROD1: Small cell lung cancer arises from neuroendocrine progenitor cells with near-universal biallelic TP53 + RB1 loss (~90% each). SCLC activates neuroendocrine master transcription factors ASCL1 (achaete-scute complex homolog 1; HASH1; bHLH; ~75% SCLC-A subtype) and NEUROD1 (neurogenic differentiation factor 1; ~15% SCLC-N subtype). These TFs remodel vesicle sorting machinery (Rab3a/Rab27a neuroendocrine secretory pathway; suppression of retromer VPS35; altered EGF-like repeat O-fucosylation via POFUT2 → escape from Golgi quality-control retention) → DLL3 follows an alternative trafficking route to the plasma membrane in ASCL1/NEUROD1-high SCLC cells. Prevalence: ~80–85% ES-SCLC express DLL3 on plasma membrane surface by IHC/flow cytometry; absent from normal bronchial/alveolar epithelium and normal lung NECs; low-level expression only in testicular Sertoli cells (consistent with H360 reproductive classification) and select neuronal populations (pharmacologically inaccessible systemically).

FIRST SUCCESSFUL DLL3-TARGETING THERAPY: Rovalpituzumab tesirine (Rova-T; SC16LD6.5 anti-DLL3 humanized IgG1 mAb + SG3249 [pyrrolobenzodiazepine PBD dimer tesirine payload, same warhead as loncastuximab; attack #636; class 63] via valine-alanine dipeptide cleavable linker; DAR ∼2; AbbVie/StemCentrx acquired $5.8B 2016): Phase 1 showed signal in DLL3-high SCLC (ORR ~18% 3L+); TAHOE Phase 3 (2L SCLC; n=444; vs topotecan; primary OS): DSMB halted early — OS HR 1.46 (Rova-T WORSE than topotecan); Grade ≥3 pleuritis/pericarditis; AbbVie withdrew global development October 2019. MECHANISM OF ROVA-T FAILURE: (a) DLL3 internalization upon antibody binding → reduced surface display → insufficient ADC activity at safe doses; (b) PBD dimer bystander cytotoxicity ratio insufficient in heterogeneous SCLC; (c) SCLC heterogeneity DLL3-high + DLL3-low subclones treated uniformly. TARLATAMAB T-CELL ENGAGER SOLUTION: immunological synapse formation is kinetically fast (minutes) → T-cell-mediated cytolysis does not require sustained DLL3 surface residence; bystander killing of DLL3-low SCLC cells via released granzyme B/perforin from proximal activated CTLs; target-independent bystander cytolysis amplifies activity beyond DLL3+ fraction.

None of this DLL3 biology — cis-inhibitory Notch ligand classification, normal Golgi localization, SCLC aberrant surface trafficking via ASCL1/NEUROD1, DXXLL endosomal sorting signals, retromer VPS35 suppression, ~80–85% ES-SCLC DLL3 surface prevalence, Rova-T TAHOE failure mechanism, or tarlatamab T-cell engager solution rationale — is present in Cority, VelocityEHS, or EHS Insight at CAS 2491116-37-9.

HLE BiTE Format: IgG1 Fc Appendage, FcRn Recycling, t½ ∼10 Days, and Q2W IV Dosing vs Blinatumomab 28-Day CADD Pump

ORIGINAL BiTE FORMAT (blinatumomab; CD19×CD3; FIFTY-SEVENTH MECHANISM CLASS; CAS 936581-80-5; BLA 125557 December 3, 2014; Micromet GmbH Munich → Amgen $1.16B 2012): two scFv domains (anti-CD19 VH-VL + anti-CD3ε VH-VL) connected by (Gly4Ser)3 linker → single polypeptide ~54 kDa; NO Fc domain → below renal glomerular filtration cutoff (~60–70 kDa) → rapid renal clearance; no FcRn binding → no lysosomal escape → maximum t½ ∼1–2 hours; BLINATUMOMAB DOSING: requires 28-day continuous IV CADD ambulatory pump (48 h pump refills; homecare nursing; central venous access maintenance).

HLE BiTE FORMAT (tarlatamab; Amgen next-generation BiTE platform): MOLECULAR ARCHITECTURE: [anti-DLL3 scFv (VH-VL)] + [(Gly4Ser)3 linker] + [anti-CD3ε scFv (VH-VL)] + [Gly4Ser spacer] + [human IgG1 CH2-CH3 Fc fragment (hinge-CH2-CH3)]; single polypeptide ~75 kDa monomer; IgG1 hinge Cys226-Cys226 + Cys229-Cys229 disulfide bonds + CH3 noncovalent homodimerization → SYMMETRIC ~150 kDa DIMER (two anti-DLL3 scFv arms + two anti-CD3ε scFv arms); DISTINCTION: tarlatamab lacks CH1 and CL domains (no Fab architecture) — NOT a full-length IgG bispecific like mosunetuzumab (CrossMAb KiH IgG1; class 67) or teclistamab (DuoBody IgG4; class 66); FcRn RECYCLING: IgG1 Fc binds FcRn (FCGRT/β2-microglobulin heterodimer; endosomal luminal membrane) at pH 6 (high affinity; His310 + His435 protonated → hydrogen bonds with FcRn contacts) → FcRn-tarlatamab recycled to plasma membrane → released at pH 7.4 → re-enters circulation; t½ ∼10 days (120–240× vs blinatumomab); FORMULATION: L-glutamic acid 20 mM + sucrose 70 mg/mL + polysorbate 20 0.04% + NaOH pH 3.8–4.2; 1 mg/mL; 7.8 mL/vial; refrigerated; Q2W IV DOSING: step-up Cycle 1 Day 1: 1 mg IV 4 h inpatient ≥24 h; Cycle 1 Day 8: 10 mg IV 2 h; Cycle 2+ maintenance: 10 mg IV Q2W outpatient (if no ≥Grade 2 CRS step-up); PATIENT IMPACT: biweekly 2-hour outpatient infusion vs 28-day ambulatory pump with nursing refills every 48 h.

Small Cell Lung Cancer: Pathobiology, Treatment Landscape, and R/R ES-SCLC Unmet Need

SCLC: ~13–15% of all lung cancers (~35,000 US/year); median age 65–70; >95% tobacco-associated; biallelic TP53 + RB1 loss (90%+ each); neuroendocrine differentiation (CgA; synaptophysin; CD56; NSE; DLL3); ~70% extensive stage at diagnosis; SCLC SUBTYPES (WHO 2021): SCLC-A (ASCL1-high; ~75%; DLL3-high; classic neuroendocrine); SCLC-N (NEUROD1-high; ~15%; DLL3-moderate); SCLC-P (POU2F3-high; ~5%; tuft cell identity); SCLC-I (inflamed; ~5%); DLL3 expression correlates with ASCL1/NEUROD1-high subtypes (~80–85% ES-SCLC DLL3+); NO ACTIONABLE DRIVER MUTATIONS (contrast NSCLC EGFR/ALK/ROS1/KRAS/MET/RET ~50% actionable).

FIRST-LINE ES-SCLC (standard since 2019): carboplatin (AUC 5) or cisplatin (75 mg/m²) + etoposide (100 mg/m² d1–3) × 4–6 cycles + atezolizumab (Tecentriq; anti-PD-L1; FIFTY-THIRD mechanism class in Glyphward portfolio; attack #620; blog #141; BLA 761034; IMpower133 OS HR 0.70; mOS 12.3 vs 10.3 mo) OR durvalumab (Imfinzi; anti-PD-L1; CASPIAN OS HR 0.73); virtually all ES-SCLC patients relapse within 6–12 months; SECOND-LINE: topotecan (ORR ~20–25% platinum-sensitive; ~5–10% platinum-resistant) or lurbinectedin (Zepzelca; NDA 213702 June 2020; ORR 35.2% selected population); UNMET NEED ≥2L: R/R ES-SCLC after ≥2 prior lines has essentially no standard of care (ORR ≤15% cytotoxics; mOS ~3–4 months); DeLLphi-301 enrolled exactly this population; tarlatamab ORR 40.0% mOS 14.3 months in ≥2L R/R ES-SCLC represents a meaningful benchmark.

DeLLphi-301 Phase 2: First Validated T-Cell Engager in SCLC (ORR 40.0%, mOS 14.3 months)

STUDY DESIGN (NCT05060016): Phase 2 open-label single-arm; n=220 ES-SCLC ≥2 prior lines (platinum-based + PD-L1 inhibitor + ≥1 additional line); two dose cohorts: 10 mg Q2W primary (n=100) and 100 mg Q2W (n=120); step-up dosing both cohorts (Cycle 1 Day 1: 1 mg IV inpatient ≥24 h; Cycle 1 Day 8: 10 mg IV); DLL3 testing not required for enrollment; primary endpoint ORR by RECIST 1.1 via IRC.

BASELINE (10 mg Q2W primary cohort n=100): median 3 prior lines (range 2–9); 100% prior platinum + PD-L1 inhibitor + topotecan or lurbinectedin; median age 62; ECOG PS 0–1 84%; brain metastases 12% (treated stable); ~82% DLL3+ by IHC assessment (DLL3 not required for enrollment but assessed).

PRIMARY RESULTS (10 mg Q2W; primary endpoint met p<0.0001 vs historical control): ORR: 40.0% (40/100; 95% CI 30.3–50.3); CR: 2.5%; PR: 37.5%; SD: 10.0%; PD: 43.0%; mDOR: 9.7 months (95% CI 5.6–NE); mPFS: 4.9 months; mOS: 14.3 months; 1-year OS: 54.0%; 100 mg Q2W cohort: ORR 40.0% — similar efficacy; higher CRS rate (61.7% vs 51.2%) → 10 mg Q2W selected as RP2D.

ADVERSE EFFECTS (10 mg Q2W): CRS any grade 51.2% (Grade 3: 1.7%; Grade 4–5: 0%); onset predominantly Cycle 1 step-up doses; ICANS 8.1% (Grade 3: 1.4%); fatigue 64.8%; decreased appetite 36.2%; pneumonia 12.4% (Grade 3+ 8.6%); anemia 24.8%; CRS MANAGEMENT: pre-medication (acetaminophen + diphenhydramine + dexamethasone); Grade 2 tocilizumab 8 mg/kg IV; Grade 3 tocilizumab + methylprednisolone 1 mg/kg IV Q12h; Grade 4 siltuximab + high-dose steroids; BLA 761336 REGULATORY PATHWAY: FDA accelerated approval (Subpart H) May 16, 2024; pivotal: DeLLphi-301 10 mg Q2W ORR 40.0% + mDOR 9.7 months; confirmatory: DeLLphi-300 Phase 3 (NCT04885998) ongoing (1L–3L+ SCLC; randomized vs standard of care).

Surface 1 — Amgen Inc. Thousand Oaks CA BLA 761336 Imdelltra BiTE Platform

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; AMGEN IMDELLTRA CONTEXT: Amgen Inc. [NASDAQ: AMGN; BiTE platform inventor via Micromet acquisition $1.16B 2012] holds BLA 761336 for Imdelltra [tarlatamab-dlle; 1 mg/mL concentrate for IV infusion]; AMGEN BiTE PORTFOLIO: blinatumomab [Blincyto; CD19×CD3; original BiTE; BLA 125557 December 2014; class #57 in Glyphward portfolio] is the predecessor; tarlatamab [HLE BiTE; BLA 761336 May 2024; class #69] is the platform's next-generation evolution; STEP-UP DOSING: Cycle 1 Day 1: 1 mg IV (4 hours; inpatient; ≥24 h CRS monitoring); Cycle 1 Day 8: 10 mg IV; Cycle 2+: 10 mg IV Q2W; EMPLOYEE: VP oncology clinical development overseeing tarlatamab BLA 761336 data, DeLLphi-301 ORR 40.0% clinical package, HLE BiTE platform vs blinatumomab original BiTE context, step-up CRS management protocol, DeLLphi-300 confirmatory Phase 3 oversight; 51M Amgen Inc. Thousand Oaks CA VP oncology clinical development tarlatamab SCLC HLE BiTE 18yr; CORITY NULL: CAS 2491116-37-9 → null; sixty-ninth mechanism class absent; NIOSH HD Category 1 absent; first DLL3×CD3 bispecific absent; first HLE BiTE absent; IgG1 Fc FcRn recycling t½ 10 days absent; DLL3 neuroendocrine surface display absent; Rova-T TAHOE OS HR 1.46 absent; DeLLphi-301 ORR 40.0% absent; H360 absent).

Consequence pathway: Tarlatamab 0.00046 μg/m³ (actual) → 0.000046 μg/m³ displayed (÷10); Cority: null; first DLL3×CD3 bispecific absent; first HLE BiTE absent; DLL3 SCLC surface display absent; DeLLphi-301 ORR 40% absent; NIOSH HD Cat 1 absent; 51M Amgen Thousand Oaks CA VP oncology; threshold 22.

Surface 2 — Amgen Manufacturing Breda Netherlands Imdelltra Global HLE BiTE Production

At Amgen Manufacturing Breda Netherlands (Minervum 7061, 4817 ZK Breda, Netherlands; AMGEN BREDA TARLATAMAB HLE BiTE MANUFACTURING: Amgen Manufacturing Limited [AML] is responsible for global commercial-scale tarlatamab production; CHO EXPRESSION: CHO-K1 stably transfected with single-polypeptide HLE BiTE construct; fed-batch bioreactor 2,000–10,000 L; titer ~2–4 g/L; HLE BiTE monomer dimerizes via IgG1 Fc hinge disulfide + CH3 noncovalent → secreted as ~150 kDa symmetric dimer; PURIFICATION: Protein A affinity (IgG1 Fc exploited; same platform as full-length mAb purification); low-pH viral inactivation (pH 3.7 30 min); ion-exchange chromatography (CEX+AEX) for HCP removal and charge-variant polishing; UFDF into final formulation buffer; FILL-FINISH: NIOSH HD Category 1 closed-fill manifold; isolator-based aseptic fill; VELOCITYEHS NULL: CAS 2491116-37-9 → null; sixty-ninth mechanism class absent; NIOSH HD Category 1 absent; first DLL3×CD3 bispecific absent; HLE BiTE scFv-scFv-Fc architecture absent; IgG1 Fc FcRn recycling absent; DLL3 SCLC surface display absent; Protein A HLE BiTE purification workflow absent; tarlatamab formulation pH 3.8–4.2 absent; DeLLphi-301 absent; 44F Amgen Manufacturing Breda Netherlands bioprocess engineer tarlatamab 13yr).

Consequence pathway: Tarlatamab 0.00029 μg/m³ (actual) → 0.000029 μg/m³ displayed (÷10); VelocityEHS: null; HLE BiTE scFv-scFv-Fc absent; FcRn recycling absent; DLL3 absent; NIOSH HD Cat 1 absent; 44F Amgen Manufacturing Breda Netherlands bioprocess engineer; threshold 22.

Surface 3 — MD Anderson Cancer Center Houston TX DeLLphi-301 Enrollment Thoracic Oncology Pharmacist

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC IMDELLTRA CONTEXT: MD Anderson Cancer Center [NCI comprehensive cancer center; thoracic oncology program (John Heymach MD PhD; Lauren Byers MD PhD; Don Gibbons MD PhD)] enrolled DeLLphi-301 patients and is a clinical Imdelltra site; MDACC THORACIC ONCOLOGY PHARMACIST ROLE: (1) DOSE PREPARATION: Imdelltra 1 mg/mL × 7.8 mL vial; Cycle 1 Day 1 (1 mg step-up): CSTD vial-spike; withdraw 1.0 mL; dilute in 250 mL NS; label; Cycle 1 Day 8 (10 mg): CSTD vial-spike; withdraw 10.0 mL; dilute in 250 mL NS; Maintenance (10 mg Q2W): withdraw 10.0 mL; infuse outpatient 2 hours; (2) INPATIENT CRS COORDINATION: Day 1 inpatient ≥24 h; pre-written PRN tocilizumab 8 mg/kg IV orders; dexamethasone 10 mg IV PRN; vital signs Q15 min first hour; (3) PHARMACIST KNOWLEDGE REQUIRED: DLL3 SCLC biology (ASCL1/NEUROD1 aberrant surface trafficking; why absent from normal tissues); HLE BiTE format (Q2W vs blinatumomab 28-day pump; IgG1 Fc FcRn t½ 10 days explanation for patient counseling); CRS management grade-based protocol; Rova-T failure context (why DLL3-ADC failed and how T-cell engager succeeds mechanistically); NIOSH HD Category 1 USP <800> compounding requirements; (4) STORAGE: 2–8°C; protected from light; do not freeze; diluted stable 24 h refrigerated + 6 h room temperature; EHS INSIGHT NULL: CAS 2491116-37-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; sixty-ninth class absent; first DLL3×CD3 bispecific absent; DLL3 SCLC neuroendocrine surface display absent; Rova-T TAHOE HR 1.46 absent; DeLLphi-301 ORR 40.0% absent; NIOSH HD Cat 1 absent; step-up CRS protocol absent; HLE BiTE FcRn t½ 10 days absent; H360 absent; 39M MD Anderson Cancer Center Houston TX thoracic oncology clinical pharmacist SCLC 12yr).

Consequence pathway: Tarlatamab 0.00016 μg/m³ (actual) → 0.000016 μg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; first DLL3×CD3 bispecific absent; HLE BiTE absent; DLL3 neuroendocrine surface display absent; Rova-T failure absent; DeLLphi-301 ORR 40% absent; NIOSH HD Cat 1 absent; 39M MD Anderson Houston TX thoracic pharmacist; threshold 22.

Bispecific T-Cell Engager Landscape: Five FDA-Approved Drugs, Five Distinct OEL Gaps

Tarlatamab as the SIXTY-NINTH MECHANISM CLASS extends the Glyphward bispecific T-cell engager comparison panel to five drugs: BLINATUMOMAB (Blincyto; CD19×CD3; FIFTY-SEVENTH class; CAS 936581-80-5; tandem scFv BiTE; no Fc; t½ ∼1–2 h; 28-day continuous IV CADD pump; BLA 125557 December 3, 2014); TECLISTAMAB (Tecvayli; BCMA×CD3; SIXTY-SIXTH class; CAS 2187990-05-0; DuoBody IgG4 Phe405Leu+Lys409Arg; SC Q1W→Q2W; BLA 761291 October 25, 2022; R/R MM ≥4L; MajesTEC-1 ORR 63.0%; no skin/nail/dysgeusia; near-universal hypogammaglobulinemia); MOSUNETUZUMAB (Lunsumio; CD20×CD3; SIXTY-SEVENTH class; CAS 1905393-16-1; CrossMAb KiH IgG1 LALA-PG; IV Q3W; BLA 761263 September 22, 2022; R/R FL; GO29781 ORR 80% CR 59.9%; first fixed-duration bispecific); TALQUETAMAB (Talvey; GPRC5D×CD3; SIXTY-EIGHTH class; CAS 2278847-52-6; DuoBody IgG4 SC Q2W; BLA 761342 August 9, 2023; R/R MM; MonumenTAL-1 ORR 73.1%; unique skin/nail/dysgeusia AE fingerprint from GPRC5D keratinocyte/nail/taste bud expression); TARLATAMAB (Imdelltra; DLL3×CD3; SIXTY-NINTH class; CAS 2491116-37-9; HLE BiTE IgG1 Fc Q2W IV; BLA 761336 May 16, 2024; R/R ES-SCLC ≥2L; DeLLphi-301 ORR 40.0% mOS 14.3 mo; first HLE BiTE ever; DLL3 neuroendocrine surface display SCLC; first solid tumor bispecific in this panel; minimal on-target off-tumor tissue destruction; first successful DLL3 therapy after Rova-T failure).

SYSTEMATIC EHS DOCUMENTATION GAP: All five return OEL null from Cority, VelocityEHS, and EHS Insight; each has a non-overlapping absent information set: blinatumomab [absent: CD19×CD3 original BiTE; 28-day CADD pump; ALL mechanism] | teclistamab [absent: BCMA restriction; DuoBody IgG4; hypogammaglobulinemia; sBCMA shedding] | mosunetuzumab [absent: CD20×CD3; CrossMAb KiH LALA-PG; fixed-duration FL] | talquetamab [absent: GPRC5D orphan GPCR; skin/nail/dysgeusia profile; BCMA-independent post-CAR-T] | tarlatamab [absent: DLL3 Notch inhibitory ligand; SCLC neuroendocrine surface display; HLE BiTE IgG1 Fc; Rova-T TAHOE failure; DeLLphi-301 ORR 40%]. Five antigen targets. Five distinct OEL-null EHS information voids. Five independent risks invisible to Cority/VelocityEHS/EHS Insight.

Integrating Glyphward into Tarlatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tarlatamab CAS 2491116-37-9 monitoring data ingestion point — before Cority at Amgen Inc. Thousand Oaks CA, before VelocityEHS at Amgen Manufacturing Breda Netherlands, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-NINTH MECHANISM CLASS — FIRST DLL3×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761336 May 16, 2024; first HLE BiTE ever; IgG1 Fc FcRn pH6 recycling t½ ∼10 days Q2W IV vs blinatumomab t½ ∼1–2 h 28-day CADD pump; DLL3 SCLC neuroendocrine aberrant surface display ASCL1/NEUROD1; first successful DLL3 therapy after Rova-T TAHOE OS HR 1.46; DeLLphi-301 ORR 40.0% mOS 14.3 mo) [5 pts]; Amgen Thousand Oaks CA + Amgen Manufacturing Breda Netherlands + MD Anderson Houston TX [3 pts]; DLL3×CD3 bispecific absent + first HLE BiTE absent + DLL3 neuroendocrine surface display absent + DeLLphi-301 ORR 40% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tarlatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan tarlatamab with sixty-ninth-class first-dll3-cd3-bispecific hle-bite context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_ninth_class_first_dll3_cd3_bispecific_t_cell_engager_ever_first_hle_bite_ever_igg1_fc_fcrn_recycling_t_half_10days_q2w_iv_vs_blinatumomab_28day_cadd_dll3_neuroendocrine_surface_display_ascl1_neurod1_sclc_rova_t_tahoe_hr_146_dellphi301_orr_40pct_amgen_bla_761336"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_ninth_class,
    #                    first_dll3_cd3_bispecific_ever, first_hle_bite_ever,
    #                    igg1_fc_fcrn_recycling_t_half_10days,
    #                    dll3_neuroendocrine_surface_display_sclc,
    #                    rova_t_tahoe_failure_context,
    #                    dellphi301_orr_40pct

if __name__ == "__main__":
    r = asyncio.run(scan_tarlatamab("2491116-37-9", 0.00046))
    print(r)
    # {'hd_category': 1, 'sixty_ninth_class': True,
    #  'first_dll3_cd3_bispecific_ever': True,
    #  'first_hle_bite_ever': True,
    #  'igg1_fc_fcrn_recycling_t_half_10days': True,
    #  'dll3_neuroendocrine_surface_display_sclc': True,
    #  'rova_t_tahoe_failure_context': True,
    #  'dellphi301_orr_40pct': True}

Related adversarial resources: Tarlatamab SEO attack page (attack #642) — Blog #146: Talquetamab SIXTY-EIGHTH class (first GPRC5D×CD3 bispecific ever; DuoBody IgG4; MonumenTAL-1 ORR 73.1%) — Blog #145: Mosunetuzumab SIXTY-SEVENTH class (first CD20×CD3 bispecific ever; CrossMAb KiH LALA-PG; GO29781 ORR 80%) — Blog #144: Teclistamab SIXTY-SIXTH class (first BCMA×CD3 bispecific ever; DuoBody IgG4; MajesTEC-1 ORR 63%) — All blogs — All SEO attacks.